MedTrace Logo

Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma

NCT01926990 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2022-02-02

No results posted yet for this study

Summary

This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Conditions

  • Metastatic Renal Cell Cancer

Interventions

DEVICE

perfusion computed tomography

Undergo perfusion CT

Sponsors & Collaborators

Principal Investigators

  • Aya Kamaya · Stanford University Hospitals and Clinics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2018-07-16
Completion
2021-12-17
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01926990 on ClinicalTrials.gov